Mersana Therapeutics, Inc. (MRSN) is a Biotechnology company in the Healthcare sector, currently trading at $29.08. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Analyst consensus target is MRSN = $3 (-89.7% upside).
Financials: revenue is $40M, +20588.3%/yr average growth. Net income is $69M (loss), growing at +18.1%/yr. Net profit margin is -170.9% (negative). Gross margin is 100% (+307007 pp trend).
Balance sheet: total debt is $29M with negative equity of -$10M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 2.19 (strong liquidity). Debt-to-assets is 19.8%. Total assets: $145M.
Analyst outlook: 11 / 19 analysts rate MRSN as buy (58%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 90/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 50/100 (Partial), Future 28/100 (Fail), Income 10/100 (Fail).
